Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financings In Brief

This article was originally published in The Gray Sheet

Executive Summary

PolyMedica probe: SEC investigation into alleged Medicare over-billing has been terminated, company announces April 8. "No enforcement action has been recommended" by the SEC to the oversight committee that was looking into the alleged fraud (1"The Gray Sheet" Aug. 13, 2001, p. 14), PolyMedica says. "We will continue to cooperate with the Department of Justice with regard to its investigation into the company as well." News of the terminated investigation sent the stock up 53%, to close at $38.90 the day of the announcement...
Advertisement

Related Content

PolyMedica Accounting Practice Draws Shareholder Class Action Suits
PolyMedica Accounting Practice Draws Shareholder Class Action Suits
Polymedica probe
Polymedica probe
PolyMedica Medicare Billing Practices In Compliance With Law, Firm Says
PolyMedica Medicare Billing Practices In Compliance With Law, Firm Says
Advertisement
UsernamePublicRestriction

Register

MT016409

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel